ClinicalTrials.gg
Active, not recruitingNCT06933329Updated Apr 15, 2026

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 2 interventional study of Zelenectide pevedotin in Non-Small Cell Lung Cancer, sponsored by BicycleTx Limited. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by BicycleTx Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain — 160 open to participants now, 334 under way, 113 of them phase 3. Carcinoma, Non-Small-Cell Lung · Spain.

Planned enrollment
616th of 797
73 · median 188
Started
2025
with 58 others
Phase 2
232 of 851
28 open now
Primary completion
2028-08
later than 219 of 333 live
Registered
787th of 851
by date

Among the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, this one is the 616th largest by planned enrollment of the 797 interventional ones that give a count, is one of 59 that started in 2025, is one of 232 in phase 2, reaches primary completion later than 219 of the 333 other live ones, and was the 787th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

160 of the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, or all of them as a file.
02

Study summary

This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • NECTIN4
  • Zelenectide pevedotin
  • Advanced or Metastatic
  • NSCLC
  • Chemotherapy
  • Non-Squamous
  • Squamous
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • or cytologically confirmed advanced or NSCLC.

    1. Cohort A: Histologically or cytologically confirmed non-squamous NSCLC.
    2. Cohort B: Histologically or cytologically confirmed squamous NSCLC.
  • Confirmed NECTIN4 gene amplification by an analytically validated clinical trial assay.
  • Participants must have received at least 1 in the advanced/metastatic setting.

    • Participants with no known actionable genomic alterations must have received both platinum based therapy and immunotherapy given either sequentially or in combination for advanced/metastatic NSCLC. Must not have received more than 3 prior lines of systemic therapy in the advanced/metastatic setting.
    • Participants with known actionable genomic alterations (eg, EGFR, ALK, BRAF, MET, ROS1, NTRK1/2/3, RET, etc.) are eligible provided they have received or are not candidates for available standard targeted therapy in the advanced/metastatic setting.
  • as defined by v1.1.
  • Adequate archival or fresh tumor tissue comprised of advanced or metastatic NSCLC should be available for submission to central laboratory, if not provided during prescreening.
  • ≥ 12 weeks.
  • Performance Status of ≤ 1.

Key Exclusion Criteria

  • Evidence of mixed small cell lung cancer (SCLC) and NSCLC histology.
  • Prior treatment with monomethyl auristatin E (MMAE) (vedotin) based therapy.
  • Known or allergy to any of the ingredients of any of the study interventions, or to MMAE.
  • Ongoing toxicity (Grade ≥ 2) associated with prior treatment for NSCLC (including radiotherapy or surgery), with the exception of well-controlled immuno-oncology related endocrine disorders on supportive or replacement therapy, and alopecia. (Note: therapies should be stopped or tapered down to ≤10 mg/day prednisone or equivalent before first study drug administration.)
  • Active keratitis or corneal ulcerations.
  • Active or untreated central nervous system (CNS) metastases.
  • Uncontrolled diabetes or hypertension.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent draining procedures (monthly or more frequently).
  • Active interstitial lung disease or pneumonitis requiring ongoing treatment with (>10mg/day of prednisone or equivalent) or other immunosuppressive medications; or any prior history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids.
  • History of another active , except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other malignancies curatively treated with no evidence of disease for ≥3 years.
  • Known requirement, while on study, for treatment with strong inhibitors or strong inducers of human cytochrome P450 3A ([cytochrome P450 3A] ) including herbal- or food-based inhibitors/inducers.
  • Prior treatment with any systemic anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to first dose of study treatment.

Note: Additional protocol defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
73 participants (estimated)

Study arms

  • Experimental
    Cohort A (non-squamous NSCLC)

    Drug: Zelenectide pevedotin

  • Experimental
    Cohort B (squamous NSCLC)

    Drug: Zelenectide pevedotin

Interventions

  • Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.

    Also known as: BT8009

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) assessed by Investigator

    Percentage of participants with either a confirmed complete response (CR) or partial response (PR)

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Number of participants reporting adverse events (AEs) and abnormalities in laboratory, electrocardiogram (ECG) and vital signs

    Safety will be reported as incidence, severity, seriousness, relationship to study treatment, and types of adverse events using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 criteria.

    Time frame: Up to approximately 3 years

  2. Duration of Response (DOR) per RECIST v1.1 assessed by the Investigator

    DoR as measured by the time from first documentation of disease progression per RECIST v1.1 or to death (due to any cause), whichever occurs first.

    Time frame: Up to approximately 3 years

  3. Disease Control Rate (DCR) per RECIST v1.1 assessed by the Investigator

    Percentage of participants with confirmed CR, PR, or stable disease (SD)

    Time frame: Up to approximately 3 years

  4. Clinical Benefit Rate (CBR) per RECIST v1.1 assessed by the Investigator

    Percentage of participants with CR, PR or SD ≥16 weeks

    Time frame: Up to approximately 3 years

  5. Progression Free Survival (PFS) per RECIST v1.1 assessed by the Investigator

    PFS is measured by the time from the first day of study drug administration (Day 1) to the first documentation of disease progression, or to death (due to any cause), whichever occurs first.

    Time frame: Up to approximately 3 years

  6. Overall Survival (OS)

    OS is defined as length of time from the first day of study drug administration (Day 1) to death (due to any cause).

    Time frame: Up to approximately 3 years

  7. Time to Progression (TTP) per RECIST v1.1 assessed by the Investigator

    TTP is defined as the time from first dose of study drug administration until first documentation of disease progression

    Time frame: Up to approximately 3 years

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2028, 37 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 37 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
Apr 18, 2025
StartActual
Jul 18, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Feb 28, 2029
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06933329
Lead sponsor
BicycleTx Limited
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
Jul 18, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Apr 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zelenectide pevedotin

Start the discussion